Brief: Neurotech International Gets US FDA Rare Pediatric Disease Designation For NTI164
08/10/2025 02:26
Oct 8 (Reuters) - Neurotech International Ltd NTI.AX: US FDA RARE PEDIATRIC DISEASE DESIGNATION FOR NTI164 IN RETT SYNDROME Further company coverage: NTI.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neurotech International
See all newsAustralia's Neurotech International slips most since April on discounted placement
Brief: Neurotech International Receives A$4 Million Placement Commitments
Brief: Neurotech International Requests Trading Halt Pending Capital Raising Announcement
Brief: Neurotech International Gets US FDA Rare Pediatric Disease Designation For NTI164
Australia's Neurotech International jumps as US FDA grants rare disease status for drug candidate